REthinking Clinical Trials


Personalized approach reduces nausea in breast cancer patients
April 15, 2021 - Cancer chemotherapy often causes nausea and vomiting, but a new clinical trial shows that a personalized approach can help. The trial, led by Dr. Mark Clemons, used a calculator his team developed to identify breast cancer patients with a high risk of nausea and vomiting.
Breast cancer patients benefit from Ottawa-based study
December 03, 2020 - There is such deep love in Gina Mertikas-Lavictoire’s eyes when she looks at her three young children. But there is something else, too: fear. Fear that one or even both of her daughters will develop the same aggressive breast cancer she’s had. So, when an opportunity arose to participate in a clinical trial through The Ottawa Hospital’s REthinking Clinical Trials (REaCT) program, she readily agreed.
Bone-modulating drugs can be given less often during cancer treatment, reducing side-effects and saving time and money
November 28, 2020 - When cancer spreads to the bones, it can cause pain, reduce mobility and increase the risk of fractures. Bone modulating drugs can help, but a new study suggests that to maximize the value of these drugs, it may be better to give them less often.
Fewer hospital visits, safer care, less cost: study changing breast cancer treatment around the world
October 15, 2020 - A new study published in Annals of Oncology shows that a drug commonly used to prevent infections in breast cancer patients can safely be given less often, meaning fewer hospital visits, fewer side effects and reduced treatment costs.
Unexpected breast cancer diagnosis leads patient down an uncertain path
October 01, 2020 - During her treatment, Annette participated in several clinical trials through The Ottawa Hospital's innovative REthinking Clinical Trials (REaCT) program. This program engages patients and their loved ones in research every step of the way, from generating ideas to setting priorities to designing studies and sharing results.
Researchers and research staff honoured for outstanding work in cancer clinical trials, emergency medicine, cell sorting and tissue collection
April 29, 2020 - A number of outstanding researchers and research teams have been honoured through The Ottawa Hospital’s Excellence Awards program for 2020. They include the Rethinking Clinical Trials (REaCT) program, Senior Clinical Research Associate in Emergency Medicine Research Manya Charette, Cell Sorting and Flow Cytometry Core Facility, and the Global Tissue Consent and Collection Platform.
Every day was a gift for Jillian O’Connor
February 04, 2019 - Eighteen weeks into her third pregnancy, Jillian O’Connor was diagnosed with breast cancer and given less than two years to live. In February 2019, she celebrated the fourth birthday of her healthy baby boy. She lived life to the fullest and championed research until she passed away on September 30, 2019.
New approach to clinical trials could revolutionize cancer care
February 23, 2017 - Yasemin Heinbecker was a career diplomat used to working 10-hour days when she received a diagnosis last fall that stopped her busy life in its tracks. Like 25,000 other Canadian women every year, she was diagnosed with breast cancer and ended up “relatively quickly on (the) couch for a dozen hours a day” while she underwent treatment.
Ottawa team pioneers new approach for cancer clinical trials
September 28, 2016 - What is the most efficient way to answer the most important questions to improve care for cancer patients? Drs. John Hilton, Mark Clemons and Dean Fergusson got a group of Ottawa researchers together to answer this question and came up eight key principles, which form the basis for their Rethinking Clinical Trials (REaCT) Program. As described in the Journal of Oncology Practice, REaCT involves comparing different approved treatment strategies rather than developing new ones. It also involves a streamlined process for obtaining oral (rather than written) patient consent, immediate randomization into treatment groups using a mobile device and simplified data collection. Their first trial, which compares two strategies to prevent chemotherapy-related infections in breast cancer patients, has recruited nearly 150 patients in just over 18 months, at a small fraction of the cost of most cancer clinical trials. Nine other REaCT cancer trials are currently underway (with support from the